Individualised care from early risk of cardiovascular disease to established heart failure


Cardiovascular diseases (CVD) are one of the leading causes of death worldwide; they affect 85 million people in Europe alone, and cases are rising due to unhealthy lifestyles and our ageing population. Despite advances in treatment, many people with cardiovascular diseases eventually develop chronic heart failure, which has a five-year mortality rate of 20 to 50 %.

Efforts to reduce the numbers of people affected by and dying from cardiovascular diseases are hampered by a number of issues. These include our incomplete understanding of how risk factors (such as diabetes and high blood pressure) influence who will develop CVD and how the disease progresses. Another challenge is the current ‘one size fits all’ approach to treating patients.

We urgently need a better understanding of CVD so that we can deliver more personalised treatments for patients, and that’s where iCARE4CVD comes in. The project aims to improve patient care across the board, starting from those at risk of developing CVD to those with advanced disease. To allow a more personalised approach to patient care, biomarkers will be used to assign those diagnosed to clinically-meaningful subgroups – this will make it easier to pick up on which patients are in most urgent need of treatment. Moreover, tools based on artificial intelligence (AI) will make it possible to predict how individual patients will respond to different treatments. Part of the project will focus specifically on people with type 1 diabetes, who are at risk of developing CVD.

The project will achieve this by gathering data on over 1 million patients from existing cohorts and providing anonymous access to the data via a blockchain-supported federated database. The project will develop AI-based models to identify different subgroups of patients and the best treatments for them. These models will be validated in large cohorts and a prospective intervention trial. Patients will be closely involved in iCARE4CVD to ensure that the project’s results meet their needs.

Ultimately, the results of iCARE4CVD will help to prevent and treat cases of CVDs, improving people’s lives and reducing the strain on healthcare systems.


  Show participants on map
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • Fondation Francophone Pour La Recherche S.R.L. Diabete, Paris, France
  • Fondazione Human Technopole, Milano, Italy
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy
  • Medizinische Universitaet Wien, Vienna, Austria
  • Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek Tno, Den Haag, Netherlands
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • Stichting Imec Nederland, Eindhoven, Netherlands
  • The Queen'S University Of Belfast, Belfast, United Kingdom
  • Thomas More Kempen Vzw, Geel, Belgium
  • Universitaetsklinikum Aachen, Aachen, Germany
  • Universiteit Maastricht, Maastricht, Netherlands
  • University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland
  • University Of Glasgow, Glasgow, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Catalyze B.V., Amsterdam-Duivendrecht, Netherlands
  • Deutsche Stiftung Fur Chronisch Kranke / German Foundation For The Chronically Ill, Furth, Germany
  • Orbital Media And Advertising Limited, Stowmarket, United Kingdom
  • Wig2 GMBH, Leipzig, Germany
Third parties
  • Bayer Healthcare Llc, Whippany, United States
  • Bayer Healthcare SAS, Loos, France
IHI industry partners
  • Amgen, Brussels, Belgium
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Dq Technologies AG, Zurich, Switzerland
  • Eli Lilly And Company, Indianapolis, United States
  • Eli Lilly Export SA, Vernier, Switzerland
  • Evotec International GMBH, Hamburg, Germany
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Huawei Technologies France, Boulogne-Billancourt, France
  • Lilly Deutschland GmbH, Bad Homburg, Germany
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Philips Medical Systems Nederland BV, Best, Netherlands
Contributing partners
  • Jdrf International, New York, United States

NameEU funding in €
Academisch Ziekenhuis Groningen703 125
Academisch Ziekenhuis Leiden312 827
Catalyze B.V.520 625
Charite - Universitaetsmedizin Berlin298 743
Deutsche Stiftung Fur Chronisch Kranke / German Foundation For The Chronically Ill493 450
Erasmus Universitair Medisch Centrum Rotterdam321 875
Fondazione Human Technopole463 729
Institut National De La Sante Et De La Recherche Medicale150 000
Istituto Di Ricerche Farmacologiche Mario Negri493 117
Medizinische Universitaet Wien293 548
Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek Tno551 560
Stichting Imec Nederland330 625
Thomas More Kempen Vzw901 938
Universitaetsklinikum Aachen996 875
Universiteit Maastricht2 482 138
University College Dublin, National University Of Ireland, Dublin326 721
Wig2 GMBH301 563
Total Cost9 942 459